Wegovy Pill Side Effects: What the FDA Label Reports

Is There a Wegovy Pill? The Quick Safety Answer

The tablet climbs through three 30-day steps before reaching its 25mg maintenance dose: 1.5mg for days 1 to 30, 4mg for days 31 to 60, 9mg for days 61 to 90, then 25mg once daily from day 91 onward. That schedule is not administrative. Escalating slowly is the lever the label uses to reduce gastrointestinal reactions, which is why the weeks around a dose change are the ones worth planning for.

Everything below separates two evidence grades that are easy to blur together: the injection's measured per-symptom rates, and the tablet's own smaller set of quantified figures. They come from different studies with different placebo arms. Keeping them apart is the whole point.

Wegovy Pill Side Effects by Dose: The 1.5 to 25mg Ladder

Where gastrointestinal symptoms cluster on the ladder

The pivotal trial behind the tablet, published as OASIS-4 by Wharton and colleagues in the New England Journal of Medicine in 2025, ran 64 weeks with a dose-escalation period of roughly 12 to 13 weeks at the front, three 30-day steps on the label's Table 2 ladder, and a 7-week off-treatment follow-up at the end. Adults were randomly assigned to oral semaglutide 25mg (205 participants) or placebo (102 participants).

Across that trial, gastrointestinal adverse events were reported by 74.0% of the semaglutide group and 42.2% of the placebo group. That is the closest tablet-specific number available for how broadly gut symptoms show up, and the placebo figure is a useful anchor: a large share of people report gut symptoms in a weight-loss trial regardless of what they are taking.

Those escalation weeks are where the schedule does its work. The label's stated reason for stepping the dose up gradually rather than starting at 25mg is to reduce gastrointestinal reactions. What neither the label nor the published trial gives is a week-by-week symptom curve, so the exact point at which nausea peaks is not something the evidence pins down.

What the FDA label actually reports for the tablet

The structural detail almost no write-up covers sits in the label itself. In the combined Wegovy prescribing information, the adverse reactions section for the tablet study does not carry its own percentage table. It states that "the types and frequency of common adverse reactions were similar to those listed in Table 3," and Table 3 is the table assembled from the injection trials.

So there is no FDA-published, per-symptom rate for any of the gut symptoms on the 25mg tablet. There is a regulatory statement of similarity to the pen's table, plus five figures from the tablet's own trial scattered across the adverse reactions and warnings sections covering discontinuation, gallstones, severe gastrointestinal reactions, and dysesthesia. The clinical studies section adds a couple more. Those five are the quantified tablet figures in the sections most people actually read, as of the label revision current in mid-2026.

Wegovy Pill vs the Injectable Pen: Tolerability Compared

The injection's measured rates (Table 3)

Table 3 in the prescribing information reports adverse reactions occurring in the once-weekly Wegovy 2.4mg injection arms (2,116 patients) against placebo (1,261 patients). Its inclusion rule matters for reading it correctly: a reaction appears only if it was reported in at least 2% of injection-treated adults and more frequently than in the placebo group. Anything below that bar, or anything no more common than placebo, is simply absent. All 19 rows are reproduced here. These are the pen's numbers.

The injection arms also reported permanent discontinuation due to an adverse reaction in 6.8% of patients versus 3.2% on placebo, with nausea (1.8% versus 0.2%), vomiting (1.2% versus 0%), and diarrhea (0.7% versus 0.1%) as the leading reasons. Our broader semaglutide side effects guide covers the same class profile across Ozempic and Wegovy.

The tablet's own quantified figures

For the 204 tablet-treated patients in the label's oral study, five quantified figures exist:

• Permanent discontinuation due to an adverse reaction: 6.9% on the tablet versus 5.9% on placebo.
• Discontinuation specifically for gastrointestinal reactions: 3.4% versus 2%.
• Cholelithiasis (gallstones): 2.5% versus 1% on the placebo tablet arm.
• Severe gastrointestinal adverse reactions: 2% on the tablet versus 0% on placebo, per section 5.6.
• Dysesthesia (altered skin sensation): 5% on the tablet versus 0% on placebo, per section 6.1.

That dysesthesia figure is worth sitting with. It is the only symptom the label counts on the tablet, the gallstone figure being a diagnosis rather than a symptom, and it is for a symptom almost nobody writing about the Wegovy pill mentions. Every gut number you see attached to the pill is borrowed from the pen. The one symptom the label does count on the tablet is a skin sensation.

The severe gastrointestinal figure is unusual in a different way: it is the only tablet figure that grades how bad the gut reactions got rather than how many people had one. It also sits in the warnings section instead of the adverse reactions tables, and is easy to miss for that reason.

The matching injection numbers, for reference, are 4.1% versus 0.9% for severe gastrointestinal reactions and 1.6% versus 0.7% for cholelithiasis. These are different denominators from different studies, so treat them as separate figures rather than a ranking. One caveat on the discontinuation number: section 6.1 gives it as 6.9%, while the clinical studies section reports the same trial at 6.8%. The label contradicts itself by a tenth of a point. This page uses 6.9%, since that is the figure in the adverse reactions section.

Why there is no verdict here

It is tempting to line up 6.9% against 6.8% and declare a winner. That comparison does not hold. The tablet figure comes from a study of 204 treated patients whose placebo arm discontinued at 5.9%. The injection figure comes from trials of 2,116 patients whose placebo arm discontinued at 3.2%. Different populations, and a placebo arm that behaved differently in each.

No head-to-head trial has compared the oral tablet against the injectable pen for tolerability, and the FDA label does not present one. Anyone stating that the pill causes less nausea, or that the pen is easier on the gut, is going beyond what the published evidence supports. The honest answer to "is the pill gentler?" is that nobody has run the study that would answer it.

Serious and Boxed-Warning Side Effects

Beyond the boxed warning, the prescribing information lists several warnings and precautions that apply to semaglutide as a molecule:

• Acute pancreatitis. Section 5.2 describes the presentation to watch for as abdominal pain that is persistent or severe, sometimes radiating to the back, with or without nausea or vomiting. Persistent counts on its own, and so does severe. You do not need both. The label directs the prescriber to discontinue Wegovy if pancreatitis is suspected, so this is a same-day call to your clinician rather than something to sit on.
• Acute gallbladder disease. Cholelithiasis and cholecystitis are both listed as warnings, and the label reports gallstone rates for the tablet and the injection arms separately.
• Severe gastrointestinal reactions. The label notes Wegovy is not recommended in people with severe gastroparesis, since delayed gastric emptying is part of how the drug works. Section 5.6 quantifies this separately for each format, covered above.
• Hypersensitivity reactions, including anaphylaxis and angioedema.
• Increased heart rate. A resting heart rate rise is documented with semaglutide.
• Hypoglycemia. Section 5.4 flags the risk, which rises when semaglutide is combined with a sulfonylurea or insulin.
• Acute kidney injury. Section 5.5 reports postmarketing cases of acute kidney injury, in some cases requiring hemodialysis, and notes that the majority occurred in patients whose gastrointestinal reactions, such as nausea, vomiting, or diarrhea, led to dehydration.
• Pulmonary aspiration during general anesthesia or deep sedation. Retained stomach contents are a documented concern, so tell any surgical or procedural team that you are on a GLP-1.
• Diabetic retinopathy complications in patients with type 2 diabetes. The label states that patients with a history of diabetic retinopathy should be monitored.

Managing Common Wegovy Pill Side Effects

None of this replaces your prescriber's instructions, and dose changes are their call. The first three items below come straight out of the prescribing information, with the section numbers so you can check them. The rest are ordinary self-management habits with no label backing, and each one says so.

• Respect the escalation schedule (label, section 2.3). The label's stated reason for the Table 2 step-up schedule is to reduce the risk of gastrointestinal adverse reactions. Holding a step longer is a decision for your prescriber, not a self-adjustment.
• Get the dosing conditions right (label, section 2.1). The tablet is taken once daily on an empty stomach in the morning with no more than four ounces of water, swallowed whole, with at least 30 minutes before any food, other drinks, or other oral medication. The Wegovy pill guide covers the procedure in full.
• Stay ahead on fluids (label, section 5.5). The label's acute kidney injury warning is specifically about volume depletion following nausea, vomiting, or diarrhea, and it tells prescribers to monitor kidney function in patients reporting reactions that could deplete volume. That is the concrete reason hydration keeps coming up.
• Smaller, more frequent meals. Not a label instruction. Delayed gastric emptying is part of how semaglutide works, per the clinical pharmacology section, and eating less at a sitting is a common practical adjustment.
• Consider easing off high-fat and heavily fried food near a step up. Not a label instruction and not something the trials measured. Some people find it helps; some do not.
• Constipation needs a different approach than nausea. Fiber, fluids, and movement are the standard general measures. They are not label guidance, and neither is any particular meal-skipping strategy.
• Track what happens and when. A prescriber deciding whether to hold a dose longer needs a timeline, not a general impression. The semaglutide dosing guide covers how titration timing is normally handled.

A physician walkthrough of the oral Wegovy tablet covering dosing and what to expect.

When to Call Your Prescriber

Expected gut symptoms and warning signs are not the same category. These are the label-derived triggers to escalate rather than wait out:

Tell any anesthesia team or proceduralist that you are taking a GLP-1 before surgery, an endoscopy, or anything requiring deep sedation, because of the aspiration warning in the label.